NuCana Announces Positive Results of NUC-1031 (Acelarin®) in Advanced Ovarian Cancer at ESMO 2017
(Thomson Reuters ONE) -
Acelarin combination with carboplatin achieved 96% disease control rate and 39%
response rate in patients with recurrent ovarian cancer
EDINBURGH, United Kingdom, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NuCana plc, a
clinical-stage biopharmaceutical company developing a portfolio of novel anti-
cancer medicines called ProTides®, announces the data presented from its
recently completed trial of its lead product candidate, NUC-1031 (Acelarin®), at
the European Society for Medical Oncology (ESMO) 2017 Congress held September
8(th)-12(th), 2017 in Madrid, Spain. Results from NuCana's Phase 1b trial showed
that Acelarin, when combined with carboplatin, was well tolerated and
demonstrated clinical activity in women with recurrent platinum-resistant and
platinum-sensitive ovarian cancer. An overall response rate of 39% was observed
amongst the 23 evaluable patients, including 1 (4%) who achieved a complete
response, 8 (35%) with partial responses, and 13 (57%) with stable disease that
lasted at least 12 weeks. This yielded an overall disease control rate of 96%
(22 patients). The responses were durable, with an average progression free
survival of 7.4 months. The most common adverse events across all dose levels
were neutropaenia, leukopaenia and thrombocytopaenia. No unexpected adverse
events were observed with the combination to date.
All patients in the study were previously treated with an average of three prior
chemotherapy regimens. Seventeen of the evaluable patients were either
refractory or resistant to their last platinum-containing regimen.
"The fact that the Acelarin combination with carboplatin achieved these results
in heavily pre-treated and platinum-resistant patients clearly demonstrates
Acelarin is a very active agent," said Dr. Sarah Blagden, Associate Professor of
Experimental Cancer Medicine at the University of Oxford and Chief Investigator
of the Phase 1b study. Professor Blagden added, "importantly, the favorable
toxicity profile of Acelarin enabled us to combine it with carboplatin at AUC
5, whereas with gemcitabine, carboplatin has to be given at AUC 4. Thus, we are
able to deliver both Acelarin and carboplatin at their optimal dose."
Hugh Griffith, NuCana's Chief Executive Officer, said: "The high disease control
rate and durable responses achieved with the combination of Acelarin and
carboplatin are exciting. We remain focused on advancing Acelarin's development
for the treatment of patients with ovarian cancer as well as exploring its use
for the treatment of other solid tumours."
About NuCana
NuCana® is a clinical-stage biopharmaceutical company focused on significantly
improving treatment outcomes for cancer patients by applying our
ProTide((TM)) technology to transform some of the most widely prescribed
chemotherapy agents, nucleoside analogs, into more effective and safer
medicines. While these conventional agents remain part of the standard of care
for the treatment of many solid tumors, their efficacy is limited by cancer cell
resistance mechanisms and they are often poorly tolerated. Utilizing our
proprietary technology, we are developing new medicines, ProTides, designed to
overcome key cancer resistance mechanisms and generate much higher
concentrations of anti-cancer metabolites in cancer cells. Our most advanced
ProTide candidates, Acelarin(®) and NUC-3373, are new chemical entities derived
from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two
widely used chemotherapy agents. Acelarin is currently being evaluated in four
clinical studies across several solid tumor indications, including ovarian
cancer, biliary cancer and pancreatic cancer. NUC-3373 is currently in a Phase
1 study for the potential treatment of a wide range of advanced solid tumor
cancers. For more information, please visit: www.nucana.com.
Forward-Looking Statements
This press release may contain "forward-looking" statements that are based on
the beliefs and assumptions and on information currently available to management
of NuCana plc (the "Company"). All statements other than statements of
historical fact contained in this press release are forward-looking statements,
including statements concerning the initiation, timing, progress and results of
clinical trials of the Company's product candidates. In some cases, you can
identify forward-looking statements by terminology such as "may," "will,"
"should," "expects," "plans," "anticipates," "believes," "estimates,"
"predicts," "potential" or "continue" or the negative of these terms or other
comparable terminology. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the Company's actual
results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking
statements. Forward-looking statements represent the Company's beliefs and
assumptions only as of the date of this press release. Although the Company
believes that the expectations reflected in the forward-looking statements are
reasonable, it cannot guarantee future results, levels of activity, performance
or achievements. Except as required by law, the Company assumes no obligation to
publicly update any forward-looking statements for any reason after the date of
this press release to conform any of the forward-looking statements to actual
results or to changes in its expectations.
For more information, please contact:
Hugh Griffith
Chief Executive Officer
+44 131 248 3660
info(at)nucana.com
Westwicke Partners
Chris Brinzey
+1 339-970-2843
Chris.brinzey(at)westwicke.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NuCana BioMed Limited via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.09.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 559613
Anzahl Zeichen: 6678
contact information:
Town:
Edinburgh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 208 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NuCana Announces Positive Results of NUC-1031 (Acelarin®) in Advanced Ovarian Cancer at ESMO 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
NuCana BioMed Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
